S&P 500   3,324.47 (+0.08%)
DOW   29,164.65 (-0.07%)
QQQ   224.45 (+0.26%)
AAPL   318.81 (+0.35%)
FB   220.43 (-0.40%)
MSFT   166.24 (+0.33%)
GOOGL   1,487.33 (+0.21%)
AMZN   1,888.09 (+0.03%)
CGC   24.26 (+0.54%)
BABA   219.53 (-1.28%)
MU   59.29 (+0.19%)
GE   11.77 (+3.52%)
TSLA   571.37 (+0.32%)
AMD   51.73 (+0.58%)
T   38.62 (-1.08%)
ACB   2.05 (+0.00%)
PRI   125.95 (-0.55%)
BAC   34.23 (-0.38%)
DIS   142.22 (-1.24%)
GILD   63.84 (+0.65%)
S&P 500   3,324.47 (+0.08%)
DOW   29,164.65 (-0.07%)
QQQ   224.45 (+0.26%)
AAPL   318.81 (+0.35%)
FB   220.43 (-0.40%)
MSFT   166.24 (+0.33%)
GOOGL   1,487.33 (+0.21%)
AMZN   1,888.09 (+0.03%)
CGC   24.26 (+0.54%)
BABA   219.53 (-1.28%)
MU   59.29 (+0.19%)
GE   11.77 (+3.52%)
TSLA   571.37 (+0.32%)
AMD   51.73 (+0.58%)
T   38.62 (-1.08%)
ACB   2.05 (+0.00%)
PRI   125.95 (-0.55%)
BAC   34.23 (-0.38%)
DIS   142.22 (-1.24%)
GILD   63.84 (+0.65%)
S&P 500   3,324.47 (+0.08%)
DOW   29,164.65 (-0.07%)
QQQ   224.45 (+0.26%)
AAPL   318.81 (+0.35%)
FB   220.43 (-0.40%)
MSFT   166.24 (+0.33%)
GOOGL   1,487.33 (+0.21%)
AMZN   1,888.09 (+0.03%)
CGC   24.26 (+0.54%)
BABA   219.53 (-1.28%)
MU   59.29 (+0.19%)
GE   11.77 (+3.52%)
TSLA   571.37 (+0.32%)
AMD   51.73 (+0.58%)
T   38.62 (-1.08%)
ACB   2.05 (+0.00%)
PRI   125.95 (-0.55%)
BAC   34.23 (-0.38%)
DIS   142.22 (-1.24%)
GILD   63.84 (+0.65%)
S&P 500   3,324.47 (+0.08%)
DOW   29,164.65 (-0.07%)
QQQ   224.45 (+0.26%)
AAPL   318.81 (+0.35%)
FB   220.43 (-0.40%)
MSFT   166.24 (+0.33%)
GOOGL   1,487.33 (+0.21%)
AMZN   1,888.09 (+0.03%)
CGC   24.26 (+0.54%)
BABA   219.53 (-1.28%)
MU   59.29 (+0.19%)
GE   11.77 (+3.52%)
TSLA   571.37 (+0.32%)
AMD   51.73 (+0.58%)
T   38.62 (-1.08%)
ACB   2.05 (+0.00%)
PRI   125.95 (-0.55%)
BAC   34.23 (-0.38%)
DIS   142.22 (-1.24%)
GILD   63.84 (+0.65%)
Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

$16.51
+0.34 (+2.10 %)
(As of 01/23/2020 03:26 PM ET)
Today's Range
$15.73
Now: $16.51
$16.74
50-Day Range
$16.17
MA: $19.38
$22.19
52-Week Range
$11.05
Now: $16.51
$31.80
Volume119,017 shs
Average Volume242,841 shs
Market Capitalization$726.94 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.68 million
Book Value$5.19 per share

Profitability

Net Income$-57,220,000.00
Net Margins-4,740.81%

Miscellaneous

Employees124
Market Cap$726.94 million
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.


Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.09. The business earned $0.44 million during the quarter, compared to the consensus estimate of $0.38 million. Homology Medicines had a negative net margin of 4,740.81% and a negative return on equity of 43.33%. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

6 Wall Street analysts have issued 12 month price objectives for Homology Medicines' stock. Their forecasts range from $29.00 to $37.00. On average, they anticipate Homology Medicines' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 99.9% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

News stories about FIXX stock have been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Homology Medicines.

Are investors shorting Homology Medicines?

Homology Medicines saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,050,000 shares, an increase of 6.6% from the December 15th total of 2,860,000 shares. Based on an average trading volume of 341,000 shares, the days-to-cover ratio is presently 8.9 days. Currently, 10.1% of the company's shares are short sold. View Homology Medicines' Current Options Chain.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Editas Medicine (EDIT), Stag Industrial (STAG), NVIDIA (NVDA), Pfizer (PFE), AT&T (T), Verizon Communications (VZ), Exxon Mobil (XOM) and Nektar Therapeutics (NKTR).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.03%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

Which major investors are buying Homology Medicines stock?

FIXX stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $16.51.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $726.94 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com/.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel